Sign up
Pharma Capital

ANGLE inks agreement with world-leading molecular testing provider

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), discusses with Proactive their co-marketing agreement with QIAGEN NV, a world-leading provider of molecular testing solutions.

The initial focus will be on prostate and breast cancer research applications.

The agreement will see both companies offering the other's products to its customer base and follows an intensive evaluation of Parsortix by QIAGEN identifying the advantages of the system.

 

View full AGL profile

ANGLE plc Timeline

Newswire

ANGLE raises another £2.8mln

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.